Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort studyEmilio Portaccio, Maria Pia Amato, Angelo Bellinvia et al.|Brain|2022Cited by 158
The effectiveness of natalizumab vs fingolimod–A comparison of international registry studiesJohanna Balslev Andersen, Gilles Edan, Sifat Sharmin et al.|Multiple Sclerosis and Related Disorders|2021Cited by 12
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Éric Berger, Raed Alroughani et al.|CNS Drugs|2021Cited by 12